B-intervention	0	10	Paclitaxel
O	11	19	improves
O	20	23	the
O	24	33	prognosis
O	34	36	in
O	37	45	estrogen
O	46	54	receptor
O	55	63	negative
O	64	76	inflammatory
O	77	83	breast
O	84	90	cancer
O	90	91	:
O	92	95	the
O	96	97	M
O	97	98	.

O	99	100	D
O	100	101	.

O	102	110	Anderson
O	111	117	Cancer
O	118	124	Center
O	125	135	experience
O	135	136	.

O	137	140	The
O	141	150	treatment
O	151	153	of
O	154	166	inflammatory
O	167	173	breast
O	174	180	cancer
O	181	189	includes
O	190	202	preoperative
O	203	216	anthracycline
O	216	217	-
O	217	222	based
O	223	235	chemotherapy
O	235	236	,
O	237	244	surgery
O	244	245	,
O	246	249	and
O	250	259	radiation
O	260	267	therapy
O	267	268	.

O	269	271	In
O	272	275	the
O	276	280	past
O	281	284	few
O	285	290	years
O	290	291	,
O	292	299	taxanes
O	299	300	,
O	301	307	mainly
O	308	318	paclitaxel
O	318	319	,
O	320	324	have
O	325	329	been
O	330	340	frequently
O	341	345	used
O	346	349	for
O	350	362	preoperative
O	363	375	chemotherapy
O	375	376	,
O	377	384	usually
O	385	387	in
O	388	396	sequence
O	397	401	with
O	402	416	anthracyclines
O	416	417	.

O	418	421	The
O	422	429	purpose
O	430	432	of
O	433	437	this
O	438	451	retrospective
O	452	460	analysis
O	461	464	was
O	465	467	to
O	468	477	determine
O	478	481	how
O	482	488	adding
O	489	499	paclitaxel
O	500	502	to
O	503	516	anthracycline
O	516	517	-
O	517	522	based
O	523	531	regimens
O	532	539	affects
O	540	549	prognosis
O	549	550	.

O	551	552	A
O	553	558	total
O	559	561	of
B-total-participants	562	565	240
B-eligibility	566	574	patients
I-eligibility	575	582	treated
I-eligibility	583	585	in
I-eligibility	586	587	6
I-eligibility	588	599	consecutive
I-eligibility	600	606	trials
O	607	614	between
O	615	619	1973
O	620	623	and
O	624	628	2000
O	629	633	were
O	634	642	included
O	643	645	in
O	646	649	the
O	650	658	analysis
O	658	659	.

O	660	665	Group
O	666	667	1
O	668	669	(
O	669	670	N
O	671	672	=
B-control-participants	673	676	178
O	676	677	)
O	678	687	consisted
O	688	690	of
O	691	699	patients
O	700	707	treated
O	708	710	in
O	711	714	the
O	715	720	first
O	721	722	4
O	723	729	trials
O	730	731	(
O	731	735	1973
O	735	736	-
O	736	740	1993
O	740	741	)
O	742	746	with
B-control	747	750	FAC
I-control	751	752	(
I-control	752	753	5
I-control	753	754	-
I-control	754	766	fluorouracil
I-control	766	767	/
I-control	767	778	doxorubicin
I-control	778	779	/
I-control	779	795	cyclophosphamide
I-control	795	796	)
O	797	802	based
O	803	811	regimens
O	811	812	.

O	813	818	Group
O	819	820	2
O	821	822	(
O	822	823	N
O	824	825	=
B-intervention-participants	826	828	62
O	828	829	)
O	830	839	consisted
O	840	842	of
O	843	851	patients
O	852	859	treated
O	860	862	in
O	863	866	the
O	867	871	last
O	872	873	2
O	874	880	trials
O	881	882	(
O	882	886	1994
O	886	887	-
O	887	891	2000
O	891	892	)
O	893	897	with
O	898	901	FAC
O	902	910	followed
O	911	913	by
O	914	924	paclitaxel
O	925	930	given
O	931	936	every
O	937	938	3
O	939	944	weeks
O	945	947	or
O	948	953	given
O	954	956	in
O	957	958	a
O	959	963	high
O	963	964	-
O	964	968	dose
O	969	975	weekly
O	976	984	schedule
O	984	985	.

O	986	989	The
O	990	991	2
O	992	998	groups
O	999	1007	differed
O	1008	1012	with
O	1013	1020	respect
O	1021	1023	to
B-outcome	1024	1030	median
I-outcome	1031	1037	follow
I-outcome	1037	1038	-
I-outcome	1038	1040	up
I-outcome	1041	1050	durations
O	1050	1051	,
O	1052	1057	which
O	1058	1062	were
B-cv-cont-median	1063	1066	148
I-cv-cont-median	1067	1073	months
O	1074	1075	(
O	1075	1080	range
O	1080	1081	,
O	1082	1084	85
O	1084	1085	-
O	1085	1088	283
O	1089	1095	months
O	1095	1096	)
O	1097	1099	in
O	1100	1105	group
O	1106	1107	1
O	1108	1111	and
B-iv-cont-median	1112	1114	45
I-iv-cont-median	1115	1121	months
O	1122	1123	(
O	1123	1128	range
O	1128	1129	,
O	1130	1132	21
O	1132	1133	-
O	1133	1135	99
O	1136	1142	months
O	1142	1143	)
O	1144	1146	in
O	1147	1152	group
O	1153	1154	2
O	1154	1155	.

B-outcome	1156	1164	Estrogen
I-outcome	1165	1173	receptor
I-outcome	1174	1175	(
I-outcome	1175	1177	ER
I-outcome	1177	1178	)
I-outcome	1179	1185	status
I-outcome	1186	1189	was
I-outcome	1190	1198	negative
O	1199	1201	in
B-cv-bin-abs	1202	1204	58
O	1205	1210	cases
O	1211	1212	(
B-cv-bin-percent	1212	1214	33
I-cv-bin-percent	1214	1215	%
O	1215	1216	)
O	1217	1219	in
O	1220	1225	group
O	1226	1227	1
O	1228	1231	and
B-iv-bin-abs	1232	1234	40
O	1235	1240	cases
O	1241	1242	(
B-iv-bin-percent	1242	1244	65
I-iv-bin-percent	1244	1245	%
O	1245	1246	)
O	1247	1249	in
O	1250	1255	group
O	1256	1257	2
O	1257	1258	.

O	1259	1264	There
O	1265	1268	was
O	1269	1271	no
O	1272	1282	difference
O	1283	1285	in
O	1286	1292	median
O	1293	1296	age
O	1297	1304	between
O	1305	1308	the
O	1309	1315	groups
O	1315	1316	.

O	1317	1320	The
B-outcome	1321	1330	objective
I-outcome	1331	1339	response
I-outcome	1340	1345	rates
I-outcome	1346	1347	(
I-outcome	1347	1355	complete
I-outcome	1356	1359	and
I-outcome	1360	1367	partial
I-outcome	1367	1368	)
O	1369	1373	were
O	1374	1381	similar
O	1382	1383	(
O	1383	1388	group
O	1389	1390	1
O	1390	1391	,
B-cv-bin-percent	1392	1394	74
I-cv-bin-percent	1394	1395	%
O	1395	1396	;
O	1397	1402	group
O	1403	1404	2
O	1404	1405	,
B-iv-bin-percent	1406	1408	82
I-iv-bin-percent	1408	1409	%
O	1409	1410	)
O	1410	1411	.

O	1412	1415	The
B-outcome	1416	1422	median
I-outcome	1423	1430	overall
I-outcome	1431	1439	survival
I-outcome	1440	1441	(
I-outcome	1441	1443	OS
I-outcome	1443	1444	)
O	1445	1448	and
B-outcome	1449	1460	progression
I-outcome	1460	1461	-
I-outcome	1461	1465	free
I-outcome	1466	1474	survival
I-outcome	1475	1476	(
I-outcome	1476	1479	PFS
I-outcome	1479	1480	)
O	1481	1485	were
O	1486	1492	better
O	1493	1495	in
O	1496	1499	the
O	1500	1508	patients
O	1509	1516	treated
O	1517	1521	with
O	1522	1532	paclitaxel
O	1532	1533	,
O	1534	1537	and
O	1538	1543	these
O	1544	1555	differences
O	1556	1563	reached
O	1564	1575	statistical
O	1576	1588	significance
O	1589	1591	in
O	1592	1595	the
O	1596	1604	patients
O	1605	1609	with
O	1610	1612	ER
O	1612	1613	-
O	1613	1621	negative
O	1622	1629	disease
O	1630	1631	(
B-outcome	1631	1637	median
I-outcome	1638	1640	OS
O	1640	1641	:
O	1642	1647	group
O	1648	1649	1
O	1649	1650	,
B-cv-cont-median	1651	1653	32
I-cv-cont-median	1654	1660	months
O	1660	1661	;
O	1662	1667	group
O	1668	1669	2
O	1669	1670	,
B-iv-cont-median	1671	1673	54
I-iv-cont-median	1674	1680	months
O	1680	1681	;
O	1682	1683	P
O	1684	1685	=
O	1686	1687	0
O	1687	1688	.
O	1688	1690	03
O	1690	1691	;
B-outcome	1692	1698	median
I-outcome	1699	1702	PFS
O	1702	1703	:
O	1704	1709	group
O	1710	1711	1
O	1711	1712	,
B-cv-cont-median	1713	1715	18
I-cv-cont-median	1716	1722	months
O	1722	1723	;
O	1724	1729	group
O	1730	1731	2
O	1731	1732	,
B-iv-cont-median	1733	1735	27
I-iv-cont-median	1736	1742	months
O	1742	1743	;
O	1744	1745	P
O	1746	1747	=
O	1748	1749	0
O	1749	1750	.
O	1750	1752	04
O	1752	1753	)
O	1753	1754	.

O	1755	1757	It
O	1758	1761	may
O	1762	1764	be
O	1765	1774	concluded
O	1775	1779	that
O	1780	1783	the
O	1784	1792	addition
O	1793	1795	of
O	1796	1806	paclitaxel
O	1807	1809	to
O	1810	1823	anthracycline
O	1823	1824	-
O	1824	1829	based
O	1830	1837	therapy
O	1838	1846	resulted
O	1847	1849	in
O	1850	1851	a
O	1852	1865	statistically
O	1866	1877	significant
O	1878	1889	improvement
O	1890	1892	in
O	1893	1900	outcome
O	1901	1903	in
O	1904	1912	patients
O	1913	1917	with
O	1918	1920	ER
O	1920	1921	-
O	1921	1929	negative
O	1930	1942	inflammatory
O	1943	1949	breast
O	1950	1956	cancer
O	1956	1957	.
